Anisha B. Patel

The University of Texas MD Anderson Cancer Center

Also affiliated with The University of Texas Health Science Center at Houston

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity”.

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

Cancer Cell(2022)10.1016/j.ccell.2022.06.006

N/A

3.9DataRank · unranked

106 citations

Jacqulyne Robichaux, Brett W. Carter, Mehmet Altan, Hai T. Tran, Don L. Gibbons +22 more

Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit

Cancer(2021)10.1002/cncr.34004

N/A

0DataRank · unranked

21 citations

Sahira Farooq, Macartney Welborn, Rodabe N. Amaria, Susan Y. Chon, Adi Diab +13 more

Power of community in “Engage for Equity PLUS” for strengthening equity-centered patient and community engaged research in academic health centers

Metropolitan Universities(2023)10.18060/27595

N/A

0DataRank · unranked

3 citations

Shannon Sanchez‐Youngman, Elizabeth Dickson, Prajakta Adsul, Michael Muhammad, Tabia Henry Akintobi +17 more

327 Data analysis for large-scale theratyping study of 656 CFTR variants

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01254-7

N/A

0DataRank · unranked

0 citations

Hermann Bihler, Linda Millen, P. Bhatt, Anisha B. Patel, J. Chin +13 more

Toxicity in the era of immune checkpoint inhibitor therapy

Frontiers in Immunology(2024)10.3389/fimmu.2024.1447021

N/A

0DataRank · unranked

61 citations

Naimah Turner, Fernanda G. Kugeratski, Rene Rico, Jocelynn Colunga-Minutti, Rayansh Poojary +13 more

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-007675

N/A

0DataRank · unranked

27 citations

Yevgeniy R. Semenov, Allireza Alloo, Daniel Q. Bach, Allison Betof Warner, Amina Bougrine +36 more

Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events

Journal of the National Comprehensive Cancer Network(2024)10.6004/jnccn.2023.7119

N/A

0DataRank · unranked

2 citations

Nicolas L. Palaskas, Bilal A. Siddiqui, Jennifer L. McQuade, Jamie S. Lin, Sumit K. Subudhi +8 more

Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy

Cancer Discovery(2021)10.1158/2159-8290.cd-20-1847

N/A

0DataRank · unranked

25 citations

Zev A. Wainberg, Anisha B. Patel, Milan J. Anadkat, Salomon M. Stemmer, Einat Shacham‐Shmueli +5 more

Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance

Journal of the European Academy of Dermatology and Venereology(2025)10.1111/jdv.20809

N/A

0DataRank · unranked

10 citations

L. Puig, Jennifer Beecker, Vinod Chandran, Joël Claveau, Javier Cortés +10 more